Combination therapy as a tool to prevent emergence of bacterial resistance (Q33961767)

30 July 2017

1 reference

title

Combination therapy as a tool to prevent emergence of bacterial resistance (English)

1 reference

30 July 2017

Mouton JW

1

1 reference

30 July 2017

publication date

1 January 1999

1 reference

30 July 2017

1 reference

30 July 2017

volume

27 Suppl 2

1 reference

30 July 2017

page(s)

S24-8

1 reference

Two compartment kinetic model with multiple artificial capillary units

30 July 2017

cites work

1 reference

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

21 January 2018

1 reference

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model

21 January 2018

1 reference

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

21 January 2018

1 reference

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model

21 January 2018

1 reference

Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats

21 January 2018

1 reference

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

21 January 2018

1 reference

Can HIV infection be cured?

21 January 2018

1 reference

12 December 2020

Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.

1 reference

12 December 2020

Treatment of ciprofloxacin- and ceftizoxime-induced resistant gram-negative bacilli.

1 reference

12 December 2020

Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

1 reference

12 December 2020

Therapy for human immunodeficiency virus infection

1 reference

12 December 2020

Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats

1 reference

12 December 2020

Use of Pharmacodynamic Parameters To Predict Efficacy of Combination Therapy by Using Fractional Inhibitory Concentration Kinetics

1 reference

12 December 2020

Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model

1 reference

12 December 2020

Therapy of neutropenic rats infected with Pseudomonas aeruginosa

1 reference

12 December 2020

The prevention of antibiotic resistance during treatment

1 reference

12 December 2020

Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium C

1 reference

12 December 2020

Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with [...]

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02561666

1 reference

Dimensions Publication ID

30 July 2017

1028679003

0 references

1 reference